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Abstract 
Extended criteria donors (ECDs) have an impact on early allograft dysfunction (EAD), biliary 
complications, relapse of hepatitis C virus (HCV), and survivals. Early allograft dysfunction was 
frequently seen in grafts with moderate and severe steatosis. Donors after cardiac death (DCD) 
have been associated with higher rates of graft failure and biliary complications compared to 
donors after brain death. Extended warm ischemia, reperfusion injury and endothelial activation 
trigger a cascade, leading to microvascular thrombosis, resulting in biliary necrosis, cholangitis, 
and graft failure. The risk of HCV recurrence increased by donor age, and associated with using 
moderately and severely steatotic grafts. With the administration of protease inhibitors sustained 
virological response was achieved in majority of the patients. Donor risk index and EC donor 
scores (DS) are reported to be useful, to assess the outcome. The 1-year survival rates were 87% 
and 40% respectively, for donors with a DS of 0 and 3. Graft survival was excellent up to a DS of 
2, however a DS >2 should be avoided in higher-risk recipients. The 1, 3 and 5-year survival of 
DCD recipients was comparable to optimal donors. However ECDs had minor survival means 
of 85%, 78.6%, and 72.3%. The graft survival of split liver transplantation (SLT) was comparable 
to that of whole liver orthotopic liver transplantation. SLT was not regarded as an ECD factor in 
the MELD era any more. Full-right-full-left split liver transplantation has a significant advantage 
to extend the high quality donor pool. Hypothermic oxygenated machine perfusion can be 
applied clinically in DCD liver grafts. Feasibility and safety were confirmed. Reperfusion injury 
was also rare in machine perfused DCD livers. 
 
I) Introduction 
As discussed earlier, extended criteria donors are used widely. In this chapter a review is given 
about the impact of ECD on the outcome. Living related liver transplantation is discussed 
shortly, whether the partial grafts can still be regarded as ECD or not.  Machine perfusion, as a 
possible management was also reviewed briefly. Outcome parameters are divided as possible 
complications, and survival results. Complications are listed as early graft dysfunction, biliary 
complications, HCV recurrence. Survival rates are summarized separately. Split, and living related 
LT discussed briefly, and finally the machine perfusion, as a possible future aspect is summarized.  
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II) Complications 
1) Early graft dysfunction (initial poor function, or delayed graft function) 
ECD donors are also not optimal for candidates with a high MELD score. Briceno et al reported 
their prediction for graft dysfunction based on ECD-scores and MELD score. In their findings 
ECD 2 (relative risk [RR]=1.59; 95% confidence interval [CI]=1.25-1.62), ECD 3 (RR=2.74; 
95% CI=2.38-3.13), as well as MELD 21 to 30 (RR=1.89; 95% CI=1.32-2.06), and MELD more 
than or equal to 30 (RR=3.38; 95% CI=2.43-3.86).were independent risk factors for IPF or PNF.  
In summary they state that a combination of ECD>3 and MELD >29 is the worst scenario [1]. 
A similar report was published by Palmiero et al about 1786 OLTs.  ECD criteria were the same as 
described earlier. The predictive factors for death among the whole population were DRI >1.5, 
cold ischemia time ≥9 hours, MELD ≥25, female recipient, and longer waiting list time [2]. 
Silberhummer et al figured out the recipients’ condition by the delta-MELD: as the difference 
between the MELD at transplantation and the MELD at listing. Patients with a both delta-
MELD>1 and an ECD>2 together had a higher chance to develop EAD, and also significantly 
higher risk for mortality [3]. Others report a similar incidence of EAD, PNF, acute rejection, 
biliary complication and also that ECD had no significant effect on either ICU stay or duration of 
postOLT ventilation, and also the postOLT laboratory test, bleeding, biliary and vascular 
complication rates were similar in ECD and non-ECD groups, and finally the rate of IPF was 
27% vs 31% in ECD and non-ECD grafted patients [4]. There was no difference (P = .882) in 
total hospital stay and ICU stay (P = .788) among recipients having three or more extended 
criteria, and also renal replacement therapy was necessary in a similar proportion in all these 
groups (P = .783) [5].  
Grafts with mild steatosis can be safely used in OLT with risk of postoperative EAD compared 
to non-steatotic grafts, if other risk factors are excluded [6,7]. The long-term outcome is also 
good.  Grafts with moderate macrovesicular steatosis (30–60%) may be utilized in the absence of 
additional risk factors in the donor or recipient; livers with more than 60% macrosteatosis should 
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probably be excluded, because the use of grafts with macrovesicular steatosis has been associated 
with increased rates of EAD, or PNF, and poorer outcome [8].  
The outcome of liver grafts with different grades of steatosis showed significantly lower patient 
and graft survival when grafts with steatosis >30% were used [7,9,10]. EAD was seen in 53% of 
grafts with moderate steatosis and in 73% of grafts with severe steatosis compared to 26% EAD 
in grafts with mild steatosis [7]. On the contrary, others demonstrated no differences in graft 
survival between grafts with less than 30% steatosis and grafts with moderate and severe steatosis 
[11,12,13]. All these studies showed that grafts with >30% steatosis had significantly increased 
transaminases, diminished PT time and longer time for bilirubin to normalize. Experience about 
the use of severely steatotic grafts is also emerging. Chavin et al. and McCormack et al. showed that 
LT with grafts with steatosis > 60%, (despite the higher incidence of EAD) can achieve excellent 
patient and graft survival when these grafts are allocated in low risk recipient [14,15]. The proper 
allocation of steatotic grafts was confirmed by Dutkowski et al.[16] : graft with <30% steatosis can 
be used safely up to BAR (Balance of Risk) score of 18 of less, however if graft steatosis exceeds 
30% acceptable outcome can be achieved only if BAR score was 9 or less. 
The definition of EAD was recently re-validated by Croome KP et al, in a multicenter study: EAD 
was a valid predictor of both graft and patient survival at six months in DBD allograft recipients, 
but in DCD ones. Within DCD group the 6 months patient and graft survival was 11,5% vs 16,7 
% with and without ECD scores. On the other hand they proved an association with INR 
more/less 1,6 on day 7 after OLT and graft failure [17]. According to the definition of Olthoff et al 
EAD was set whether of one or more of the following previously defined postoperative 
laboratory analyses were present: bilirubin >or=10mg/dL on day 7, international normalized 
ratio >or=1.6 on day 7, and alanine or aspartate aminotransferases >2000 IU/L within the first 7 
days. Of recipients meeting the EAD definition, 18.8% died, as opposed to 1.8% of recipients 
without EAD (relative risk = 10.7 [95% confidence interval: 3.6, 31.9] P < 0.0001). More 
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recipients with EAD lost their grafts (26.1%) than recipients with no EAD (3.5%) (relative risk = 
7.4 [95% confidence interval: 3.4, 16.3] P < 0.0001) [18]. This is in accordance with the definition 
of Nemes et al [19]. Routh et al report 6,5% PNF, and 26,1% of three or more complications in 
ECD grafted recipients [20]. PNF is usually defined as unrecoverable hepatocellular dysfunction 
leading to patient death or re-transplantation within the first week post-transplant after excluding 
other causes of graft failure such as vascular thrombosis, biliary complications, rejection or 
recurrent disease. By using different in vivo organ preservation methods to maintain DCD 
donors and by strictly applying donor selection criteria authors report promising results from 
Maastricht category I and II donors with a PNF rate of 10%-25% [21]. Leithead et al reported 
about the kidney injury that developed frequently after DCD grafting. Acute kidney injury 
occurred 53,4% vs 31,8% in DCD vs DBD grafted patients, while chronic renal impairment was 
found to be  53,7% vs 42,1% respectively [22].  
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2) Biliary complications 
i) Donor organ quality 
The development of biliary complications after liver transplantation has been described as the 
Achilles of the operation. Extended criteria donors, steatotic liver, prolonged CIT are risk factors 
for biliary complications [23]. The risk will even be higher, when additive risk factors are present 
on the recipient side. Nemes et al [19] compared different study groups, which were established 
according to donor graft quality and recipient status. Donors had a marginal score if any of the 
following were present: age older than 60 years, BMI greater than 27, ICU stay longer than 3 
days, high inotropic support, hypotension, cardiac arrest requiring cardiopulmonary resuscitation, 
hypernatremia, elevated liver enzymes or serum bilirubin levels. Recipient status was based on 
MELD scores; and the results showed that patients with a high MELD score demonstrated 
increased risk of postoperative complications - including biliary complications. Moreover the use 
of marginal donor organs in high-risk patients increased early patient mortality. If possible, an 
extended criteria organ must never be given to a recipient with extensive risk factors. Other 
authors found similar biliary and vascular complication rates in ECD and non-ECD groups [4, 
24,25].   
ii) The role of hepatic artery thrombosis 
Hepatic artery thrombosis (HAT) must also be mentioned as a serious technical complication, 
occurring in approximately 2% to 9% of cases. Early HAT frequently results in fulminant hepatic 
failure, bile duct necrosis and leaks, relapsing bacteremia and ultimately graft loss and 
retransplantation or recipient death [26]. Several factors have been reported to predispose to 
HAT [27]. The role of advanced donor age is controversial. Petridis et al [28] reported OLTs from 
cadaveric donors older than 80 years with 10% of HAT, also requiring retransplantation. As for 
the late complications 60% had stricture of the biliary anastomosis.  In case of older donors - the 
iliac "tool kit" may be unusable because of atherosclerotic disease. An alternative solution is to 
perform the anastomosis of the celiac artery with aortic patch from the donor directly to the 
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supraceliac aorta of the recipient [29]. In the more recent approach to hepatic artery (HA) 
reconstruction the use of interposition grafts was minimized. Cescon et al. suggest performing 
more “straight” anastomoses on sites generally spared from advanced stages of atherosclerosis, 
thus reducing the risk of kinking and of disruption of the intima [27]. 
iii) Split liver transplantation 
Postoperative morbidity, composed of vascular and biliary complications, remains high for 
pediatric and adult recipients of split liver transplantation (SLT). Vagefi et al analyzed data of 106 
SLT recipients and found 29% biliary and 11% vascular postoperative complications and 11% 
unplanned re-exploratory surgery in adult recipients, and 40% biliary and 26% vascular 
complications in children [30]. The complication rate for recipients of living donor liver allografts 
is still higher than that for recipients of whole-organ allografts, which is further compounded by 
the morbidity and mortality risk of the living donor [30]. Mallik et al found similar incidence of 
biliary complications when comparing DCD and SLT liver transplants [31]. The splitting 
procedure –in the case of ex vivo splitting technique - takes typically 2–3 hours and additional 
time required for transport of these livers (possibly to two centers sequentially), consequently 
SLT has much longer CIT than DCD has. 
iv) Donors after circulatory death (DCD), ischemia-reperfusion 
Many publications focus on liver transplant complications related to DCD transplantation, the 
increasing special form of ECD pool. DCD liver transplantation has been associated with inferior 
outcomes including higher rates of graft failure and biliary complications compared with DBD 
transplants [26,32]. DCD recipients have a 2.4 times increased Odds-ratio of biliary 
complications and a 10.8 times increased odds of ischemic cholangiopathy (IC) [26,33]. IC 
patients experience jaundice, disabling pruritus, and frequent episodes of cholangitis [33]. DCD 
recipients with IC experienced more frequent re-hospitalizations, longer lengths of stay, and 
required more invasive biliary procedures. According to a metaanalysis of Jay et al IC patients 
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undergo an average of 12 invasive biliary procedures (range = 0–21) in their first 2 years after 
transplantation [33]. Skaro et al [34] observed no significant differences in the rates of PNF or 
vascular complications, but the majority of re-listing (69.2%) and re-OLT (71.4%) in the DCD 
group were a consequence of biliary complications. After OLT the development of IC is most 
commonly precipitated by the occlusion of hepatic arterial flow. Yamamoto et al. found 
significantly more HAT (33.3% vs. 0%) and biliary (37.5% vs. 6.3%) complications in their DCD 
group compared to the DBD group [35]. After DCD OLT, warm ischemia, preservation and 
reperfusion injury involving the peribiliary plexus have been implicated. Endothelial activation 
triggers a cascade of events leading to microvascular thrombosis and ischemia resulting in 
stricture formation, biliary necrosis and cholangitis culminating in progressive graft failure [34]. 
Abou Abbass et al [36] also reported 46% of biliary complications after DCD OLT. These donors 
undergo variable periods of hypoperfusion between extubation and asystole, and another period 
of no perfusion between asystole and cold flush, meaning a significant ischemic insult. Biliary 
strictures may occur with a patent hepatic artery (IC or ischemic-type biliary strictures (ITBS)). 
These lesions associate with increased incidence of abscess formation and lower graft survival 
and higher mortality. The treatment options include endoscopic retrograde cholangio-
pancreaticography (ERCP), percutaneous transhepatic cholangiography (PTC) and drainage 
(PTD), conversion to hepaticojejunostomy with Roux-en-Y limb, artery revision if necessary. 
Less severe IC can be treated without retransplantation as long as the strictures are few and 
accessible for endoscopic or percutaneous therapy. Patients with bilateral multifocal strictures, or 
diffuse necrosis of the bile ducts had poor prognosis resulting in either death or 
retransplantation. Foley et al found that 81% of their DCD retransplants were for complications of 
IC [37]. High retransplantation rates have important ramifications for healthcare costs and the 
pool of available livers. Costs associated with retransplantation are more than double those for 
primary transplantation [33].  
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Factors such as a long WIT, chaotic donor physiology before asystole, and bile salt toxicity are 
believed to lead to a higher risk of non-anastomotic biliary stricture [26,38,39]. The biliary 
epithelium is more sensitive to ischemia/reperfusion injury than hepatocytes. The injury to the 
biliary epithelium may occur before or after organ retrieval because of the depletion of energy 
stores. The combination of donor warm ischemia and subsequent cold ischemia/reperfusion 
increases the generation of oxygen free radicals within the biliary epithelium. Ischemic injury to 
the microvascular endothelium in the preservation phase also leads to cell disruption, loss of 
surface glycosamino-glykans (heparin) and may contribute to microvascular thrombosis. This 
may prevent effective revascularization and worsen ischemic injury to the biliary epithelium [36]. 
Foley et al also found a significantly higher rate of HAS in the DCD group. These stenoses were 
all distal to the anastomosis and they hypothesized that the artery may have sustained some 
ischemic injury secondary to the DCD recovery and implantation process [37]. 
It has been suggested an arterial flush at the back table in addition to portal flush. Flushing the 
arterial tree with thrombolytic solution could help eliminate microthrombi and aid biliary tree 
perfusion. [38]. Some investigators have proposed that initial reperfusion through the arterial 
system or simultaneous portal and arterial reperfusion might decrease the occurrence of non-
anastomotic biliary strictures [38,39]. It would lead to faster reperfusion of the biliary tree, 
thereby minimizing warm ischemia time. Lopez-Andujar et al recommend the use of T-tube in the 
presence of any risk factors for biliary complications, such as a donor or recipient bile duct 
diameter of less than 7 mm, large discrepancies between bile duct sizes, split or reduced grafts, 
DCD donors, retransplantations and to control the quantity and quality of bile in the immediate 
posttransplant period [40,41,42]. Long WIT seems to be detrimental to biliary tree and graft 
survival in general.  
According to Foley et al CIT and donor age are the strongest predictors for the development of IC 
[37]. Chan et al found donor age of more than 50 years to be a significant risk factor for biliary 
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complications [26,43]. Donor weight >100 kg in combination with long total ischemic times and 
older donor age are predictive risk factors for the development of IC [26,37]. Moreover, 
transplanting a liver with> 25% of steatosis is a risk factor for the development of biliary 
complication [44]. 
Some have reported the use of histidine-tryptophan-ketoglutarate (HTK) to be associated with 
lower rates of biliary strictures than the use of University of Wisconsin (UW) solution while 
others have found no such difference [26]. Due to these observations some liver transplant 
centers decline DCD livers if the agonal phase exceeds 30 minutes and/or CIT exceeds 10 hours, 
livers from donors more than 40 years old and use HTK solution during procurement. 
Extracorporeal membrane oxygenation (ECMO) may provide adequate normothermic organ 
perfusion and oxygenation in the absence of cardiac function. This has the potential advantage of 
eliminating the period of hypoperfusion of organs during the agonal phase and lessening the 
warm ischemic time associated with the DCD process. Clinical initiatives using ECMO suggest a 
potential to protect both hepatocytes and biliary epithelium [36,39].  Fondevilla et al reported using 
ECMO from declaration of death until organ procurement and the clinical applicability of type 2 
DCD liver transplants was 9% (34 OLT out of 400 potential donors) [45]. Biliary complications 
occurred in four recipients (12%). There were three cases of IC (8%), who underwent 
retransplantation, a fourth patient developed an anastomotic biliary stricture and successfully 
underwent hepaticojejunostomy. 
The higher rate of ITBS in DCD liver transplantation leads to higher recipient morbidity 
including biliary sepsis, growth of multi-resistant organisms and deteriorating health status, which 
eventually might exclude those recipients from relisting. In the current era of MELD-based 
allocation, these patients can only regain true access to a retransplantation through an exceptional 
MELD status, as suggested by Monbaliu et al [46]. 
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The summarized results of ECD and Hepatitis C recurrence as well as the patient-, graft 
cumulative survival are shown on Table 1 and 2. Due to the extensive publication of these topics 
the results of some authors (Ref.No.118 to 138) will only appear on the Tables. 
3) Hepatitis C recurrence (Table 1.) 
In the era of organ shortage the donor factors affecting HCV recurrence are in the focus of 
interest. 
i) Donor age 
As mentioned in the first part, donor age steadily increased over recent years. Older donors have 
been found to be associated with HCV recurrence and worse patient and graft survival [47]. In 
the report by Lake et al., donor age (>40 years) was the strongest predictor of graft loss and death 
in patients with HCV, however, this was not a risk factor in HBV or in patients without viral 
etiology [48]. There is a clear association between donor age and accelerated fibrosis progression 
in HCV patients. Donor age was a powerful determinant (p=0.02) of fibrosis progression rate in 
HCV patients. When the liver donor was younger than 40 years, median progression rate was 0.6 
units/year and interval to cirrhosis was 10 years. When the donor was aged> 50 years, median 
progression rate was 2.7 units/year and interval to cirrhosis only 2.2 years [49]. Uemura et al. 
reported advanced donor age (>60 yrs.) has led to poor outcome of OLT for HCV regardless of 
MELD score and recipient age using the UNOS database [50]. Estimation by Botha et al. showed 
the risk of HCV recurrence increased by 23% for every 10-year increase in donor age [51]. Others 
reported that young donor age would be also a risk factor for HCV recurrence, and found no 
decrease in short term graft or patient survival using young pediatric donors (<13 yrs.) in adult 
recipients[52]. 
ii) Hepatic steatosis  
It is found in about 15-25% of potential liver donors [53]. In 2007, Briceno et al. published a paper 
analyzing 120 patients with HCV and they reported liver grafts with moderate-to-severe steatosis, 
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those with severe liver preservation injury and prolonged CIT showed a dismal prognosis at 1, 3, 
and 5 years. Upon multivariate analysis, fat content and CIT >12 hours were independent 
predictors of graft survival [54]. Also more frequent and earlier HCV recurrence have been 
reported using moderately and severely steatotic grafts (>30%), concluding to avoid OLT with 
30% steatotic donor livers in HCV recipients [55].  Contrary, Botha et al. analyzed 113 HCV 
positive LT candidates declaring that macrovesicular steatosis (5–45%) had no impact on HCV 
recurrence. Only donor age (P = 0.02) and CIT (P=0.01) were found to increase the relative risk 
of HCV recurrence [51]. Similarly to this report, Burra et al. reported no correlation between 
steatosis and fibrosis progression in HCV patients. They examined serial liver biopsies after liver 
transplantation in 56 hepatitis C virus–positive and 60 HCV negative patients. No difference in 
36-month survival was seen, regardless of whether the etiology of the patient’s liver disease was 
HCV-related or non–HCV-related and whether the steatosis in the graft was reportedly absent, 
mild, or moderate/severe [56].  
iii) Allocation, preservation injury 
As for HCV recurrence, a positive correlation between both CIT and WIT and severe HCV 
recurrence and reduced survival has been shown [47]. As mentioned previously, prolonged 
ischemia time is an independent risk factor associated, particularly for allografts from donors >60 
years old [55]. In the study by Botha et al, the risk of HCV recurrence increased by 13% for every 
1-hour increase in CIT [51]. HCV recipients with evidence of graft reperfusion injury have been 
shown to have poorer survival outcomes when compared with non-HCV transplant patients. In 
case of reperfusion injury, hepatocyte death and proliferation, it is possible that the viral burden 
may increase dramatically by incorporating into proliferating cells [57]. In fact, PI may be a result 
of a combination of several perioperative factors that define the ECD donor, including 
prolonged ischemic time, donor age, and donor steatosis [47]. 
iv) Antiviral therapy 
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Considering the growing number of ECDs and a high proportion of HCV positive recipients, an 
effective treatment of HCV recurrence is the challenge. Since the standard PEG-IFN+RBV 
therapy had low response rate and high intolerability, the use of direct-acting antivirals (DAAs) 
are in the focus of interest.  In 2011, the first generation protease inhibitor (PI) boceprevir (BOC) 
and telaprevir (TLV) have been approved by the Food and Drugs Administration for 
immunocompetent patients in association with PEG-IFN and RBV [58]. Pungpapong et al 
compared viral response in 35 LT patients who received TLV plus PEG-IFN and RBV to 25 
patients who received BOC plus PEG-IFN and RBV. After 24 weeks of treatment, 67% of TLV-
treated and 45% of BOC-treated patients achieved HCV-RNA negativity [59]. In a recent study 
safety and efficacy of triple therapy after OLT have been analyzed, and 42% SVR rate after TLV 
based and 53% in BOC based triple therapy was found [60]. The rate of serious adverse events 
was 27% and hematological toxicity was seen in 95%. Excellent results have been shown 
regarding IFN free regimens: Charlton M et al. evaluated the efficacy and safety of an IFN-free 
regimen of the nucleotide polymerase inhibitor sofosbuvir (SOF) combined with RBV for 24 
weeks in 40 patients treating post-transplantation compensated recurrent HCV infection. SVR at 
12 weeks after treatment was achieved in 70% patients [61]. SOF and RBV regimen is also well-
tolerated and it seems to be effective against fibrosis [62]). More data regarding the use of these 
novel DAAs in different groups of ECD donation are needed. However, these results are 
encouraging to transplant centers that make an effort to expand the donor pool by safely using 
even HCV positive donors for a transplant. 
III) Survival (Table 2.) 
1) Waitlist mortality 
This is reported already in 2009 by Burroughs et al that the number of patients awaiting an OLT 
has tripled to 18.000, and organ availability increased only from 1.700 to 6.200 grafts per year 
[63].  Despite expanding the definition of acceptable deceased donor grafts and employing partial 
grafts from living donors, death on the liver waiting list still occurs in approximately 8% of the 
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candidates. The summary of Barshes NF et al questions whether the waitlist mortality (WLM) 
decreases at a given transplant center by using ECDs [64].  The study of Barshes NF et al might be 
regarded as referential for the ECD topic since they have been collecting the data of all US 
transplant centers between February 2002 and June 2005.  That covered the data of 100 US liver 
transplant centers, meaning a total of 15,932 liver transplantations. These operations included 
11660 (73,2%) standard criteria donor grafts, and 3555 ECDs (22,3%), while 717 transplantation 
were carried out by living donor liver transplantation (LDLT).  The waitlist mortality varied from 
0 to 15,3%, while the median number of liver transplants performed using an ECD allograft/ 
waitlist candidate was 0.09 (0-0,26).  They introduce the coefficient ECD that means the number 
of liver transplants performed using ECD liver allografts (as defined above) at center during the 
study period divided by the total number of candidates added to the waitlist at center during the 
study period. Using a cross-sectional multivariate regression analysis they prove that waitlist 
mortality will be decreased by about 1% for every additional ECD liver transplant per 100 waitlist 
candidates (p=0,003). Yet ECD liver allografts are often allocated to less severely ill transplant 
recipients that have a lower risk of pretransplant mortality, so it could not be tacitly assumed that 
the use of these allografts would necessarily decrease WLM [64].  The question that arises in the 
paper of Barshes NF et al is still open for discussion: would it be better to increase the use of ECD 
sin liver transplantation by gaining 1-5% of waitlist mortality and having a post-transplant 
survival of 70%, or be much more selective, and strict to optimal donors that result in a 15% 
waitlist mortality but resulting in a 90% post-transplant survival? Other centers even quantified 
the increase in their activity by the introduction of ECD program. Waitlist mortality was 8% 
reported by Gastaca in Spain where 1392 recipients were listed during 2007, and 1045 were 
transplanted [65].  
2) Patient survival, mortality 
Some reports suggest that a graft-related death occurs in 8.5% of recipients of EDC grafts versus 
4.2% of recipients of optimal grafts [4]. Articles presenting data about survival after ECD are 
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summarized in Table 2. In the study of Afonso et al the early mortality rate (within 30 days) didn’t 
differed among liver transplanted patients with one, two, three or more extended criteria. They 
have prospectively recorded data from 139 patients who underwent 152 OLTs. Early overall 
survival rate was 83.76%; 12 reOLTs were required (10.25%). Comparing the four groups, patient 
survivals (P =0.41) and retransplantation rates (P =0.518) were similar [5]. Angele et al proved that 
organ survival did not depend on the degree of donor steatosis (5-year-survival rates: 68% and 
58% with steatosis <30%, or >/= 30%, respectively) (hazard ratio .754, confidence interval .458-
1.242, P = .268) [66]. Bacchella et al also report high mortality within the first month, in cases of 
marginal grafts transplanted into high-MELD recipients. On the other hand, high-MELD 
recipients of non-marginal livers achieved an adequate survival rate [24]. In contrary Gruttadauria 
et al report on a worse but, non-significant patient survival drop in ECD. It means that regardless 
of having one, or more criterions present, the cumulative patient survival didn’t differ 
significantly. However graft survival was  93,22% vs  78,9% at 6 months. Despite this fact, it was 
suggested that a more aggressive acceptance of ECDs, did not negatively influence the overall 
outcome [25,67]. Others also report a similarly good early survival, and only 13% one-year 
mortality in ECD group [20]. In a from the UNOS database with 117 comparing 117 grafts from 
controlled DCD with a group of DBD grafts, the PNF rate was 11.8% versus 6.4%, respectively 
(P= .008) while the 1-year graft survival was 72.3% versus 80.4%, respectively (P= .056). Patient 
survivals were similar but the retransplantation rate was higher among the DCD group, 13.9% 
versus 8.3% (P= .04) [68]. According to the UCLA database in 2009, 1153 liver allografts were 
considered, and 568 of them exhibited no extended criteria (donor score = 0), and 429, 135, and 
21 donors had donor scores (DS) of 1, 2, and 3, respectively. The overall 1-year survival rates 
were 87%, 80%, 77%, and 40%, respectively, with donors with a DS of 0, 1, 2, and 3. Graft 
survival was excellent up to donor score 2, but grafts from donors with a DS >2 should be 
avoided, particularly in higher-risk recipients [72].  Nguyen et al compared DCD, SCD and ECD 
groups. The one-, three-, and five-year survival of DCD recipients was 89.5%, 89.5%, and 89.5%, 
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respectively. This was not significantly different than patient survival at one-, three-, and five-year 
for SCD (84.3%, 80.7%, 76.5%) and ECD (85%, 78.6%, 72.3%) groups [69].  
Briceno et al. reported about 498 patients that received an ECD liver, 13.25% of whom had a HRS 
prior to OLT. They revealed that graft macrosteatosis per-30%-increments and donors >65 yrs. 
(p = 0.089; HR = 1.622 [1.17-1.94]) were independent predictors of graft loss in recipients with 
HRS.  In this context, for patients with type 1 HRS, to receive a graft from an aged donor and/or 
moderate-to-severe graft steatosis may be better than waiting for an optimal donor. However, the 
combination of donors >65 yrs. with a >60% graft steatosis may not be recommended in type 2 
HRS because of the high rate of graft dysfunction in a patient not so sick, who may wait for a 
better donor [70].  Jay et al revised the US Scientific Registry of Transplant Recipients database 
between 1996 and 2007, and collected the data of 1113 DCS and 42,254 DBD operations. The 1 
and 3 years patient survival was 82% and 71%, as well as 86% and 77% respectively [32].  Harring 
et al studied the UNOS/OPTN database for DCD and DBD graft and patients 1, 3, 5 and 10 
years survival.  For patients it was 84,4%, 74,8%, 68,9% and 48,8% vs 86,1%, 78,3%, 72,5%, and 
59% respectively. For grafts it was 75,3%, 63,9%, 56,2% and 38,7%, vs. 81,5%, 72,8%, 66,5%, 
and 52,8% [71]. In other reports  DCD grafts with ≥ 3 donor risk factors had significantly lower 
1-year post-transplant survival than no or only 1 or 2 risk factors (58.3% vs 72.6%, 69.2% and 
73.9%, respectively). No grafts with 4 risk factors survived within 1 year [26]. 
In the comprehensive review of le Dinh H et al the results of 13 major overviews has been 
summarized: DCD recipients more often require re-transplantation. Respectively, 21.6%-42% vs 
8.8%-16% of DCD and DBD recipients were listed for re-transplantation. The retransplantation 
rate ranged from 7.6% to 31% in DCD-LT compared to 2.5%-12% in DBD-LT [26]. 
Retransplantation arouses controversy on medical, economic, and ethical grounds: patient and 
graft survival rates after a second liver transplant are inferior to those after initial grafting, the 
procedure is more expensive and in the context of organ shortage retransplantation inevitably 
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denies organs to first-time recipients [72]. Retransplantation rate was significantly higher in case 
of DCD vs DBD (14,7% vs. 6,8%) in the largest studies, like the one of Jay’s in 2011, and re-
transplantation survival was markedly inferior to survival after primary transplant irrespective of 
graft type [32].  The use of extended criteria liver donors for retransplantation is controversial.  In 
the study of Northup et al 1327 retransplantations were analyzed.  There were 611 (46%) recipients 
who received re-livers from a donor with at least one ECD criterion [72]. Among the 165 
patients reported by Schemmer et al there were 23 secondary OLTs (13.9%; 13 no-EDC [17.6%] vs 
10 EDC [11%] P = .2), and four tertiary OLTs (2.4%): two in each group; (2.7% vs 2.2%; P = 
.9). [4]. Utilization of DCD allografts for re-transplantation was rare (2.5% of initial DCD vs 
3.1% of initial DBD) and outcomes from each group were comparable. The general practice is to 
avoid re-transplantation with a DCD graft [26]. This topic is further discussed by Marti et al: 88 
non-urgent liver retransplantations were studied. Grafts with a Donor Risk Index> 1,8 were 
considered as high risk. They also divided OLTs for two time periods. In the first period high-
risk grafts did worse than low-risk grafts (5-year survival: 0 vs. 54.5%, p=0.002) while in the 
second period outcomes were similar (5-year survival: 48.6 vs. 56.7%, p=0.660). Donor age was 
the only independent donor factor for graft survival, with lower survival when using grafts from 
donors over 60-years-old [73]. In summary controlled DCD became a fast growing source for 
OLT. Consequently, DCD nowadays represents as much as 20% of the liver donor pool in some 
European countries.  There are differences among the countries. For example, the use of 
controlled (Maastricht category III) DCD donors is not legal in Spain, France and Hungary. 
Between 2004 and 2009 the proportion of DCD increased from 0,5% to 1,9% in Spain 
(Maastricht-II), but from 2,4% to 18,6% in Belgium, and from 7,5% to 21,7% in The 
Netherlands [74]. 
IV) Split and living related transplantation 
Earlier the reduced size livers, and split liver grafts were told to be extended criteria. Split-liver 
transplantation (SLT), a technique that allows for the use of two liver grafts from one donor liver, 
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is a good alternative to increasing the donor pool. Conventional splitting along the falciform 
ligament increases the number of left lateral segment grafts, shortens the pediatric waiting list and 
reduces the pre-transplant mortality of children [75,76]. On the other hand, early reports of 
inferior results for extended right lobe graft (eRLG) transplantation compared with whole liver 
transplantation (WLT) have discouraged aggressive use of the SLT technique, and eRLGs are 
considered to be marginal grafts [31]. Recently, technical improvements achieved with careful 
donor and recipient selection have had favorable results [77]. Cauley et al. reported the findings of 
an analysis of 62,190 liver transplantation procedures in adults (889 SLT) based on the UNOS 
data obtained in 2013. In that report, the graft survival of SLT was comparable to that of WLT 
(P=0.66), and the authors demonstrated that SLT was a significant risk factor of increased graft 
failure in the pre-MELD era (1995-2001), but not the MELD era (2002-2010) [78].  
Another multicenter study reported similar results for 382 eRLG transplantations. The survival 
rates in a group of patients undergoing 358 primary eRLG transplantations at 1, 3 and 5 years 
were 85.2%, 82.5% and 82.5%, respectively, in the current period (2005-2011), which were 
significantly better than those noted in the previous period ((1997-2004); 80.0%, 68.9% and 
66.1%, respectively). However, the outcomes of 24 re-transplantation procedures performed 
using eRLG were extremely poor, with 1-, 3- and 5-year survival rates of 16.7%, 12.5% and 
12.5%, respectively [79]. Factors related to the outcomes of SLT have been reported to include a 
recipient MELD score of > 30, age of > 60 years, donor age of >45 years, CIT of >10 hours, 
urgent recipient condition and treatment at a low-volume center [80]. Complications after SLT 
were recently discussed in a meta-analysis conducted by Wan et al., which showed higher rates of 
overall biliary complications (OR=1.66, 95% CI= 1.29-2.15, P<0.001), bile leakage (OR=4.30, 
95% CI=2.97-6.23, P<0.001), overall vascular complications (OR=1.81, 95% CI=1.29-2.53, 
P<0.001), HAT (OR=1.71, 95% CI=1.17-2.50, P=0.005) and outflow tract obstruction 
(OR=4.17, 95% CI=1.75-9.94, P=0.001) in cases of eRLG transplantation. However, 
comorbidities were not found to be significant risk factors for either patient or graft survival [81].  
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The method for splitting can be divided into two types. Ex vivo splitting involves usual organ 
procurement followed by parenchymal dissection and vessel division on the back table. This 
technique is not influenced by donor hemodynamic instability and allows for rapid parenchymal 
resection, which contributes to a short warm ischemia time [77]. However, identifying various 
vital structures may be difficult in this setting. In order to overcome this problem, careful 
inspection using angiography and cholangiography is an alternative [30]. In situ splitting has the 
advantages of a short cold ischemia time and the ability to precisely detect the vessels. On the 
other hand, the prolonged splitting time, inconvenience for graft procurement and possibility of a 
prolonged WIT due to donor hemodynamic instability are potential disadvantages. The results of 
these two techniques are conflicting [30,81].  
From the perspective of increasing the donor pool for adult recipients, full-right-full-left split 
liver transplantation (FRFLSLT) may have a significant advantage. However, because of technical 
and organizational difficulties, experience with this technique is limited [82]. In particular, 
anatomic variation, the small graft size and difficultly in performing vascular anastomosis and 
biliary reconstruction are crucial matters. In addition, despite the importance of evaluating the 
graft size and obtaining vascular information, the use of preoperative multiphase computed 
tomography in deceased donors is controversial, both logistically and ethically [83]. In 2014, a 
multicenter study from Italy reported a high postoperative complication rate in patients treated 
with FRFLSLT (64.1% Clavien grade III and IV) and a lower 5-year survival rate than that 
associated with WLT (63.3% and 83.1%) [84]. On the other hand, Lee et al. recently reported their 
experience with 42 FRFLSLT procedures. In that report, the postoperative complication rate was 
35.7% (Clavien grade III and IV) and the 1-, 3-  and 5-year survival rates were comparable with 
those of living donor liver transplantation (71.4%, 69.0%, 69.0% and 79.9%, 75.1%, 70.4%, 
respectively), despite being allocated to patients on the waiting list with the highest MELD 
scores. The authors suggested that the criteria for this procedure should include recipients with a 
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GRWR of more than 1% in cases of FRFLSLT, considering the uncertain condition of the 
donated liver [83]. 
V) Machine perfusion in the management of ECD liver grafts (Table 3.) 
Different liver retrieval techniques for DCD have been described in the early nineties, including 
femoral cannulation prior to withdrawal of life support, and to as the ‘‘super-rapid technique’’ 
[74]. The extent of ischemia reperfusion injury depends on the degree of activation of key players 
involved in the hepatic ischemia reperfusion injury including Kupffer cells, platelets and 
leukocytes, besides the generated pro-inflammatory response (oxidative stress, inflammatory 
cytokines, and cytoplasmic proteases, up regulation of pro-inflammatory transcription factors). 
Clinically, ischemia reperfusion injury can result in immediate graft function, delayed graft 
function (considered to occur in 10–30% of grafts) or primary graft non-function (considered to 
occur in < 5% of grafts respectively) [45].  
Referring to Vekemans study [85], simple cold storage (SCS) fails to optimally preserve extended 
criteria organs, alternative preservation methods potentially might be more beneficial. Relevant 
methods are shown in Table 3. During machine perfusion (MP) continuous circulation is 
maintained, the microcirculation is better preserved. In contrast to SCS, MP organs can be 
monitored over time; viability markers can be identified. Monbaliu et al evaluated discarded human 
livers after hypothermic machine perfusion (HMP). The livers were classified as non-
transplantable and (in retrospect) transplantable according to generally accepted clinical criteria. 
They used HMP as a screening-tool to distinguish transplantable from non-transplantable ECD 
human liver grafts that were rejected for LT [74]. With SCS, the sinusoids become constricted 
due to the hypothermia, which prevents the penetration of the preservation solution in to the 
tissues and may cause an impaired microcirculation upon reperfusion [85]. Although MP has 
been developed to limit ischaemic graft damage and it has a proven biochemical benefit, machine 
liver perfusion is not yet considered clinically due to its low practicability. In a mini-review of 
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Dutkowski et al there is a summary about the different types of machine perfusion methods [86]. 
The use of normothermic and hypothermic perfusion solutions are the possibly two ways of MP 
technics, both with advantages and disadvantages. In Obara’s article also a subnormothermic 
preservation temperature is mentioned [87]. Most of the published MP techniques do not 
consider practicability because it is generally recommended to apply perfusion immediately after 
organ harvest and during the whole preservation period. From a clinical point of view, perfusion 
during organ transport would be unavoidable which bears the risk of perfusion failure due to 
logistic reasons. In contrast, authors suggest a short-term MP performed after arrival of the 
harvested donor organ at the centre. A period of approximately 1–2 h usually accumulates after 
completion of back table preparation which allows interventions on the preserved and prepared 
graft during recipient hepatectomy without delay of the transplant procedure. Either hypothermic 
oxygenated low-pressure perfusion or normothermic asanguineous oxygenated perfusion are 
conceivable [86]. De Rougemont et al demonstrated in their large animal model the efficacy of a 
simple cold oxygenated MP system to rescue, otherwise lethal, ischemic injured DCD liver grafts 
[88]. In this study authors carried out OLT in Swiss landrace pigs, carefully adapted as close as 
possible to human situation. Some livers were treated by 1 hour hypothermic oxygenated 
machine perfusion prior to implantation (HOPE-group). They demonstrated that pigs 
transplanted with DCD grafts developed severe and uncorrectable acidosis, systemic shock, and 
severe liver injury evident by histology and liver function. All pigs with such untreated grafts died 
within a few hours after OLT due to PNF of liver grafts. In contrast, a short term machine 
perfusion was highly successful in preventing all of these events, resulting in extubation of 
transplanted pigs 2 hours after reperfusion, normalized lactate, initiated bile flow and 
improvement in histology [88]. According to Schlegel et al, HOPE may offer many beneficial 
effects, not only by rescuing marginal grafts but also by preventing rejection and decreasing the 
need for immunosuppression [89]. Dutkowski et al presented in 2013, the first report showing that 
this novel technique of HOPE can be applied clinically in human DCD liver grafts without 
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apparent increase of adverse outcome. In this initial report, they thus indicate feasibility and 
safety of such an approach, and also confirm that reperfusion injury was low in machine perfused 
DCD livers despite prolonged donor WIT. Authors also documented excellent early and longer-
term outcome, and particularly no intrahepatic cholangiopathy in machine perfused DCD liver 
grafts [90]. Similar to the former studies many experiments with animal models investigate the 
potential clinical role of MP. The aim of the study of Bessems et al [91] was to compare cold 
storage and MP for preservation of the steatotic donor rat liver. Their method was the following: 
liver steatosis was induced in male Wistar rats by a choline-methionine-deficient diet. After 24 
hours hypothermic cold storage (CS) using the UW solution or MP using UW-Gluconate (UW-
G), liver damage and liver function were assessed in an isolated perfused rat liver model. 
According to their results, MP had an advantageous effect on bile production, oxygen 
consumption of the liver during reperfusion and on AST and lactate dehydrogenase (LDH) 
release. In accordance with other studies, Bessems concluded the evidence that steatotic livers are 
better preserved by MP instead of SCS. Preservation of steatotic livers by hypothermic MP 
results in less liver damage and better liver function as compared to SCS [91]. Franchello et al 
evaluated the role of ischemic preconditioning (IP) of the liver. 75 deceased liver donors were 
randomized to receive IP (IP+) or not (IP−). The main groups of (IP+) and (IP−) were divided 
in two subgroups considering the quality of the graft (marginal+ and marginal−); IP was 
performed during the procurement procedure by 10min inflow occlusion followed by 30min of 
reperfusion prior to the start of cold ischemia [92]. The analysis confirmed the hepatoprotective 
action of IP; a significant reduction of hepatocytes suffering was seen in IP+ graft when 
analysing cellular swelling after homeostatic deregulation. Preconditioning significantly increased 
low-grade and reduced mild-grade swelling. Olschewski et al evaluated in their study the influence 
of the perfusate temperature during oxygenated MP on the graft quality. Wistar rats were 
harvested after 60min warm ischemia induced by cardiac arrest. The portal vein was cannulated 
and the liver flushed with Lifor (Lifeblood Medical, Inc.) organ preservation solution for 
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oxygenated MP at 4, 12 or 21C’. After MP at 21C’, portal venous resistance was significant 
reduced and bile flow was higher. Perfusion at 12 and 21 C’ resulted after 6 h machine perfusion 
a significant higher enzyme release compared to machine perfusion at 4 C’ After 60 min of 
normothermic reperfusion, livers stored static at 4 C’ revealed a significant elevated enzyme 
release compared to livers stored by MP [93].  
In connection with various organs (heart, brain) erythropoietin (rHuEpo) has been shown to be 
protective against ischemic damage and improving posttraumatic organ function. Schmeding et al 
evaluated the potential effect of rHuEpo preconditioning and treatment on post-transplant graft 
function in a rat model of marginal graft liver transplantation [94]. rHuEpo has been used in 
clinical routines for many years and can be regarded as a fairly safe substance with few side 
effects. Therefore, the application of rHuEpo in conditioning the “marginal” donor organ before 
and at/after transplantation may serve as a valuable tool in improving organ function after LT of 
extended liver grafts. The study of Mangus et al compares HTK and UW in a large number of 
SCD and ECD livers at a single centre over 5 years in Indianapolis [95]. All together 698 liver and 
liver-kidney transplants were analysed. HTK and UW were found to have no statistically 
significant difference in post-transplant graft and patient survival, risk of intraoperative death, 
and graft failure in the first 7 days post-transplant. Livers preserved with HTK had a higher initial 
AST and ALT in SCD and physiologic ECD livers, whereas the UW-preserved livers had a 
higher AST and ALT in the old donor livers. In all groups, these differences disappear by 
postoperative day 7. Only in case of biliary complications seemed the HTK to be superior to 
UW, including any need for biliary evaluation and the presence of bile duct stones or sludge. 
Stegemann et al have compared different types of perfusion solutions in case of MP in marginal 
liver grafts [96]. They concluded in their study that the results provided evidence for enhanced 
organ protective potential of the new Custodiol-N solution (complete modified HTK solution, 
i.e., with the addition of two iron chelators: 25 mM deferoxamine, and 7.5 mM of the new, 
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membrane-permeable chelator LK 614) compared with HTK solution upon hypothermic 
machine preservation of marginal liver grafts.  
Vogel highlights in his abstract the current challenges of MP in liver transplantation. According to 
this, first the feasibility of the normothermic MP methodology in human livers has to be 
confirmed and, second, we have to develop and introduce a functional device into the clinical 
arena [97]. Since the phase I clinical trial of liver HMP has suggested superiority over SCS 
preservation, HMP has the potential to predict graft function as well as enable resuscitation of 
grafts from ECD [98]. In the year 2010 Guarrera et al published the results of the first study 
comparing HMP to standard cold preservation in human LT (clinical phase 1, prospective cohort 
trial) [99]. HMP occurred during patient preparation and recipient hepatectomy thus only a 
portion of the cold ischemic period was perfusion time. This simplifies the technique and allows 
utilization of less portable perfusion devices. The results have confirmed the beneficial effect of 
MP. EAD rates were 5% in the HMP group versus 25% in controls (p = 0.08). At 12 months, 
there were two deaths in each group, all unrelated to preservation or graft function. There were 
no vascular complications in HMP livers. Two biliary complications were observed in HMP livers 
compared with four in the CS group. Serum injury markers were significantly lower in the HMP 
group. Mean hospital stay was shorter in the HMP group (10.9 ± 4.7 days vs. 15.3 ± 4.9 days in 
the CS group, p = 0.006). HMP of donor livers provided safe and reliable preservation in this 
pilot case-controlled series. Connected to the former study, in another report [100] the authors 
examined levels of soluble cytokines, including interleukin-1 receptor antagonist (IL-1Rα), which 
is an anti-inflammatory member of the interleukin (IL) family produced in response to nuclear 
factor kappaB (NF- κβ) activation or IL-1β and IL-6 stimulation, and monocyte chemotactic 
protein-1 (MCP-1/CCL2), which is a monocyte and natural killer cell chemoattractant secreted 
by endothelial cells and monocytes in response to IL-1 signalling. These markers of immune 
activation during ischemia and reperfusion can provide an insight into the mechanism of HMP–
mediated ischaemia-reperfusion injury (IRI) resistance and act as signals of future IRI damage in 
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the liver graft after reperfusion. Obara et al have developed a MP preservation system that 
controls the perfusate temperature from hypothermic to subnormothermic conditions [87]. The 
porcine livers were perfused with modified UW gluconate solution containing dextran. The 
temperature was increased gradually from 4–8°C to 23°C during the perfusion. The pressure 
transition in the hepatic artery measured with this system was employed as a liver viability 
evaluation index. Temperatures controlled MP had a positive effect on pressure transition in the 
hepatic artery, and after this method lower LDH levels were found. In conclusion the results of 
Obara support the advantages of temperature-controlled MP to preserve the liver graft [87]. 
Guarrera reports 21 ECD livers that were preserved with HMP in phase 2 clinical trial also 
highlights that their experience with liver HMP is the only reported clinical experience worldwide 
representing a total of 41 successful liver transplant cases showing improved outcomes and 
diminished markers of ischemia/reperfusion injury. [99,101]. 
Various cytoprotective substances have been successfully administered into the donor prior to 
cardiac arrest for prevention of liver microcirculatory disturbance. Up to now, only Heparin and 
phentolamin (an antithrombotic substance and alpha-adrenergic antagonist) are allowed in clinical 
DCD organ procurement [26]. Tacrolimus, milrinone (a type 3 phosphodiesterase inhibitor), 
lazaroids (iron-dependent lipid peroxidase inhibitor), N-acetyl-cysteine were also studied in 
animal models [26]. Perhaps the most effective step in organ preservation is the cooling of the 
organ as the metabolic rate is halved for every 10 C drop in temperature [74].  
VI) Expert commentary 
When talking about extended criteria liver grafts we should emphasize that the functional reserve 
of these livers are limited. There is a sensitive balance between protective factors (like shortened 
CIT, WIT, machine perfusion, proper recipient selection) that will keep the results optimal and 
further injuries that cause decomposition. Injuries can be ischemia related or other (like viral 
exposure), however they will, at least partly act through the Ito cells. These cells (perisinusoidal 
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fat-storing cells, stellate cells, and lipocytes) are mesenchymal cells located in the space of Disse. 
[102]. When hepatic stellate cells (HSCs) are subjected to stress such as hypoxia, oxidative stress 
or endoplasmic reticulum stress, they modulate fibrosis progression by induction of their 
activation toward a myofibroblastic phenotype, or by undergoing apoptosis, and thus helping 
fibrosis resolution [103]. General inflammation pathways also lead to liver fibrosis. HCV 
infection is also associated with the development of hepatic fibrosis. Whether HCV is able to 
enter and replicate in hepatic stellate cells (HSCs), thereby directly disturbing their metabolism 
and activating them, is unknown. The results of Florimond et al, suggest that HCV infection of 
HSCs does not play a role in their activation and the related fibrogenic process during the course 
of chronic HCV infection [104]. Ductular reactions are encountered in virtually all liver disorders 
in which there is organ-wide liver damage and cell loss, but are also present in focal lesions such 
as focal nodular hyperplasia and adenoma. Moreover, diverse ductular reaction phenotypes can 
be present within any single disease entity, and are shaped by the etiology and evolution of the 
disease. Although much remains to be clarified, recent studies suggest that the diversity of 
appearances of the ductular reactions are likely to reflect the differing signals at the anatomic, 
cellular, and molecular levels driving the proliferative response [105]. The study cohort of Prakoso 
et al had 194 biopsy samples from 105 individuals with HCV recurrence after LT. The 
immunophenotype, morphology, and location of the ductular reaction were consistent with a 
hepatic progenitor cell origin. The ductular reaction correlated with intrahepatic fibrosis 
(P < 0.001) and the number of activated hepatic stellate cells (HSCs; rs = 0.446, P < 0.001) [106]. 
Donor Risk Index has been developed by Feng et al in 2006 [107]. Whereas a DRI of 1 or less was 
associated with an 87.6% 1-year survival, it was 76.9% for a DRI of 1.6 to 1.8 and 71.4% for a 
DRI > 2. This is also reported by our group in 2010, that allocation of an ECD donor to „bad” 
condition recipients is a worst scenario, while ECD donors might serve well in an HCC patient 
with mild cirrhosis [19]. According to other relevant authors the donor risk factors for a graft 
failure in case of ECD are antiHBcore AB positivity, low arterial pressure for more than 20 
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minutes, and CIT > 6 hour [108]. Prolonged CIT are inevitable proven as a worsening factor in 
case of ECD [32]. Therefore some argue for the withdrawal of life support in the operating room 
rather than in the ICU or preoperative holding unit. The need to transport donors from these 
locations to the operating room after declaration of cardiac death could further increase warm 
ischemia times and diminish the quality of livers [108].  ET uses several criteria to define a 
marginal donor or an ECD. None of the other ECD criteria (except for donor age) were found 
to have a significant impact on transplantation outcomes. The term ECD is still controversial 
because there is no recognized definition of an ECD. The DRI could be useful in defining what 
kind of donor should be considered an ECD [109]. Due to ethical and legal differences DCDs 
are utilized only in certain countries. A homogenous guideline for the management is not 
possible to set. However in the review of Monbaliu D et al this is suggested to optimize the 
outcome by donor pretreatment, avoid extended WIT, rapid flush out with low viscosity solution, 
allocation the liver to the procuring center (diminish CIT), add cytoprotective agents to the 
perfusion solution, use ex vivo, machine perfusion, and/ or in vivo ECMO perfusion, carefully 
select the recipient [73].  In large cohorts, a higher DCD graft failure within the first 180 days 
(20.5% DCD vs. 11.5% DBD; P < 0.001) is demonstrated, with convergence thereafter. 
Allocation policy that recognizes this limitation and increases access to ReOLT is necessary for 
expansion of this donor population [110]. Ethical aspects should also be considered. The first 
results of the ELITA-ELTR coordinated questionnaire was published by Bruzzone P et al based on 
the answers of 35 centres accepting ECD donors. Thirty-one centers informed the 
transplantation candidate of the ECD status of the donor, 20 (65%) when the patient registered 
for transplantation, 1 (3%) when an ECD liver became available, and 10 centers (32%) on both 
occasions. Thirteen centers required the liver transplantation candidate to sign a special consent 
form. Twenty centers informed the potential recipient of the donor's serology. Only 6 centers 
informed the potential recipient of any high-risk behavior of the donor [111]. Ischemia-
reperfusion injury (I/R) is one of the negative impacts that might worsen the outcome of ECDs. 
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We suggest the study of Nemeth et al concerning the importance of changes in hemorheological 
parameters caused by acid-base and blood gas alterations in experimental surgical models [112]. 
According to the authors conclusion [113] the majority of these harmful effects can be 
preventable by antioxidant drugs. Ischemic time and temperature are determinant factors in the 
extent of changes. The real extent of local micro-rheological changes is still unclear, and mainly in 
the context of microcirculatory disturbances further investigations are required. 
Machine perfusion is an example of co-operation among health-care managers, medical 
professionals and bioengineer-experts. Since the 1960s, the most commonly used method of 
preserving organs for clinical transplant has been static cold storage (SCS). Machine perfusion 
generates a controlled recirculating flow of preservative solution at hypothermic temperatures in 
the 0°C to 4°C range. It is generally accepted that expanded criteria donor kidneys are liable to 
draw the greatest benefit from MP. It may be beneficial only in certain DCD subsets; reducing 
DGF, in DCD donors younger than 60 years old and 1-year survival in donors older than 50 
years. The renal MP protocols cannot be applied directly to liver transplant, but need to be 
adapted to account for these distinctions, which include hepatic and portal systems flow 
competition, hepatic sinusoidal endothelial cell susceptibility to damage, high liver metabolism, 
the MP effect on preventing biliary tree injury, and Kupffer cell activation. The question of 
optimal temperature optimal flow rates and perfusion pressures, single or dual vessel perfusion, 
perfusate oxygenation, and different perfusate compositions are still under investigation [114]. 
The challenge in the era of new antiviral agents is the realistic approach, to completely resolve the 
HCV recurrence as a problem. [115]. HCV as a main indication for LT, and a current highlight in 
recurrent diseases, will be replaced by NASH within a few decades. 
During living related donor liver transplantation this is expected to perform the splitting on an 
excellent donor liver. This is mandatory for the benefit of the donor and the recipient as well. 
Therefore it seems hard to find a connection between LRLT and extended criteria donors. 
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However LDLT practice is becoming the major alternative to bridge the gap between waitlist and 
final surgery not covered by current deceased donor procurement. From a centre perspective the 
inevitable utilization of ECDs can be partly replaced by an LRLT program. That can be 
exceptionally true for certain indications, like adult-to adult LRLT in high-urgency patients 
(Model for End-Stage Liver Disease score >30), or extended application of LDLT for 
unresectable hepatocellular carcinoma above Milan criteria [116].  The main field of LRLT is still 
pediatric LT (pLT) programs. Analyses of the collaborative transplant study (CTS) database show 
LDLT rates in pLT of 33%. The long-term graft survival is significantly better after LDLT vs 
DDLT (5-year graft survival 78.2% in LDLT vs 71.4% in DDLT, P < 0.001). The advantages of 
LDLT are the use of an optimal healthy donor, minimal ischemic time, elective surgery and 
timing of transplantation according to the recipients’ need, which is particularly relevant for 
pediatric patients. [117] 
VII) Five year view 
In the near future, due to the significant lack of deceased donors in Western countries, full 
right/full left splitting (FRFLSLT) may become widely accepted at experienced centers at which 
living donor liver transplantation is frequently performed. Machine perfusion might offer 
potential strategies to decrease the grade of steatosis in livers procured for transplantation. 
Pharmacological preconditioning during normothermic machine perfusion was successfully used 
in experimental setting. Normothermic machine perfusion might also allow assessing the viability 
of steatotic graft before transplantation. More ECD livers will be preserved with MP techniques 
in clinical trials. Protocols are needed to determine with exact parameters of whether an ECD 
liver is transplantable or not. The need of ECD livers will stimulate the production of MP 
systems that are mobile, portable and available for all liver transplant centers. Other methods 
such as the use of HuEpo can also increase the transplantable liver pool. With the modern 
hemorheological instruments and standards new opportunities have been provided for the 
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experimental surgical research work, also for investigating the pathophysiology of circulation and 
microcirculation in ischemia-reperfusion injury. The use of DAAs will completely change the 
indications map of OLTs in ten years. As a consequence of successful treatment of HCV with 
DAA, the NASH (non-alcoholic steatohepatitis) will become the leader cause for an OLT. The 
usage of HCV positive liver grafts will not be considered as an ECD in five years, since a proper 
DAA treatment will offer complete remission, and protection for a HCV relapse.  
ECDs are useful and safe when the meantime one consider the maximum protection of the 
recipient and graft, with donor preconditioning, prevention of ischemia-reperfusion, machine 
perfusion if needed, proper recipient selection, modern intensive care, and combined updated 
antiviral treatment. Ongoing and novel targets of basic research are welcome to enhance these 
fields and put them into practice. 
VIII) Key issues 
• The main complications after transplanting an ECD graft are the initial poor function 
(delayed graft function, or early allograft dysfunction), the late non-surgical biliary 
complications, and the recurrence of HVC/HBV. In case of an ECD graft 
transplantation a prolonged and complicated ICU care of the recipient should be 
anticipated 
• Improvements in the outcomes of conventional split liver transplantation have 
encouraged the use of eRLG grafts as well as whole liver grafts, except for cases of re-
transplantation. On the other hand, more experience with FRFLSLT is required. These 
grafts continue to be considered “marginal” because of the small graft size and associated 
technical complexity. However, in the near future, due to the significant lack of deceased 
donors in Western countries, FRFLSLT may become widely accepted at experienced 
centers at which living donor liver transplantation is frequently performed. 
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• In the last years more and more studies are available evaluating the positive effects of 
machine perfusion on human liver grafts. Still evidences and clinical trials are needed to 
accept and routinely use the MP techniques in the clinical therapy during liver 
transplantation. 
• We live in the era of new antiviral agents implemented in case of HCV recurrence after 
OLT. Clinical trials have offered robust evidence supporting the use of direct antiviral  
(DAA) agents as pioneer treatments, alone, or in combination with standard pegylated 
interferon (peg-IFN) and ribavirin (RBV)-based regimens. DAAs have proved highly 
efficacious, with pan-genotypic activity, shortened treatment duration, and an improved 
side-effect profile when compared with historical peg-IFN/RBV treatment. 
• According to the allocation policies the correct approach is a balance between individual 
justice (serving individuals in need) and population utility (getting the best results for the 
entire population at risk) 
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Table 1: Outcome of liver transplantations (survival, HCV recurrence, liver fibrosis) after the use of ECD in HCV positive recipients and 
the impact of anti-HBsAg/anti-HBc positive donors. 
Author Year No. ECD End-point Impact/outcome Notes 
Briceno et 
al.[54] 
2009 125 HCV + steatosis Time of reHCV Facilitate 
 
ECD risk >30% 
steatosis 
Pt/Graft Survival Worsened 
Burra et 
al.[55] 
2009 56 HCV+ 60 HCV - steatosis Pt/graft suvival No impact Longterm liver 
graft histology Fibrosis 
Briceno et 
al.[53] 
2007 120 HCV+ Multiple* Graft survival Worsened *CIT, 
reperfusion 
injury and 
steatosis>30% 
Botha et 
al.[50] 
2007 113 HCV+ steatosis reHCV +fibrosis No impact  
CIT, age reHCV +fibrosis Accelerate 
Subramanian 
et al. [114] 
2012 48 HCV+ Steatosis Fibrosis 
+cytokine 
Accelerate Fibrosis at 1 
year post OLT 
Uemura et 
al.[49] 
2012 7508 HCV+ Age (>60) Graft survival Worsened Additional risk 
factor was 
DCD, CIT  
Ghabril et 
al.[51] 
2009 51 HCV+ Age 
(>=13) 
Pt/graft survival No difference  
Time of reHCV  
Fibrosis 
DCD  
Yagci et 
al.[115] 
2008 14 HCV/DCD 
188 HCV/DBD 
DCD Pt/Graft survival worsened  
Hernandez-
Alejandro et 
al.[116] 
2011 17 HCV/DCD 
15 HCV- 
42 HCV/DBD 
DCD PT/graft survival worsened Control group 
42 
HCV+/DBD- 
Taner et 
al.[117] 
2011 77 HCV/DCD 
77 HCV/DBD 
DCD Pt /graft survival No difference  
Fibrosis 
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Uemura et al. 
[118] 
2012 630 HCV/DCD 
1164HCV-/DCD+ 
13257 HCV+/DBD 
DCD Graft/Pt survival HCV+  no difference 
HCV-  worsened 
UNOS 
database 
Controlled 
DCD 
Tao et 
al.[119] 
2010 37 HCV/DCD 
74HCV/DBD 
DCD Pt/graft survival No significant 
difference 
 
reHCV 
fibrosis 
Author Year No. End-point Impact Notes 
Anti-HCV positive donors 
Northup et 
al. [120] 
2010 741 HCV+/HCV+ 
18760 HCV-/HCV+ 
Pt/Graft Survival No difference US OPTN Registry 
Database 
Ballarin et 
al.[121] 
2011 63 HCV+/HCV+ 
63 HCV-/HCV+ 
Pt/Graft suvival No difference European multicenter 
study reHCV  timing Accelerated (NS) 
 severity Accelerated (NS) 
Burra et 
al.[122] 
2011 540 HCV+ donor 
540 HCV- donor 
Pt/Graft survival No difference UNOS dabase 
442 HCV+/HCV+ 
442 HCV-/HCV+ 
O'Leary et 
al.[123] 
2012 32 HCV+/HCV+ 
17/32 HCV RNA - 
Graft/Pt survival No difference 17/32 HCV RNA neg 
Fibrosis 
Anti-HBsAg negative, anti-HBc positive donors 
Yu et al.[124] 2009 1270 aHBc+  donor 
34350 aHBc- donor 
 
Pt/Graft survival 
 
No difference 
UNOS database 
 
MacConmara 
et al.[125] 
2012 25 aHBc + donor 
843 aHBc - donor 
Pt/graft survival No difference aHBc +  and MELD 
>30 worsened early 
survival 
De novo HBV None 
Angelico et 
al. [126] 
2013 1218 HBc - donor 
219 HBc + donor 
Graft survival Worsened Liver Match 
prospective 
observational cohort 
study from in Italy 66 HBc+/HBsAg + 
153 HBc+/HBsAg - 
No difference 
Worsened 
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Table 2: Main post OLT complications, cumulative patient and graft survival in relation to ECD 
 
 Standard vs EC donors 
 Year Remark N of 
OLTs 
ECD 
(%) 
EAD (IPF) 
(%) 
BC (IC) 
(%) 
reOLT 
(%) 
Patient survival (%) Graft survival (%) 
        1-6 mths 1 yr 3 yr 5yr 10 yr 1-3 mths 1 ys 3 5 10 
Abt[67] 2004  43 367 25,6 
(DCD only) 
n.d n.d   85 vs 
79,7 
77,4 vs 
72,1 
       
Barshes[63] 2007 WL 
mortality= 
1% 
decrease 
by 1 ECD 
/100 OLT 
15 932 22,3              
Lucidi[127] 2007  70 44 10 vs 13   90 vs 90          
Northup[71] 2007 all HCV+ 
all reOLT 
1 327 46     70,9 70,8         
Schemmer[4] 2007  165 55     82 vs 76 75 vs 74        
Silberhumer[3] 2007  386 ECD all: 65 
ECD>1: 29 
ΔMELD>1 
+ECD>2: 
HR=3.78, p=0,01 
            
Afonso[5] 2008 ECD 
score: 
0-4 
139 43,6   1= 0 
2= 9,4 
3= 15,8  
4= 7,7 
 1= 85 
2= 83 
3= 89 
4= 69 
        
Bachella[23] 2008  103 63,1   5,2 vs 10,8 95 vs 80          
Gruttadauria[24] 2008  115 49,5 3,4 vs 7 29,3 vs 
30 
0 vs 5,2 95 vs 83 94,8 vs 
81 
(2yrs) 92 
vs 81 
       
Selck[109] 2008 DBD vs 
DCD 
21 944 39   8 vs 21,6  84,4 vs 
73,8 
74,4 vs 
57,6 
       
Gastaca[64] 2009 donor age 
< 55 vs 
>75 
 n.a no impact          69,5 
59,8 
 51 
45,6 
Burroughs[128] 2009 DBD vs 
DCD 
552 9 2,6 vs 5,5 9 vs 21  83 vs 83  74 vs 70   79 vs 77  69 
66 
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Continued Table 2. 
Skaro[33] 2009 DCD vs 
DBD 
269 11,9 (DCD) 3,1 vs 0,4 
(PNF, DCD vs 
DBD) 
53,1 vs 
21,5 
21,9 vs 6,8 DCD vs 
DBD 
74,0 vs 
90,4 
74,0 vs 
80,7 
  DCD vs 
DBD 
61,3 vs 
85,2 
52,6 vs 
74,2 
  
Abou Abbas[35] 2010 DCD 491 5,2 (DCD) 0,0 (PNF) 46 26  92     77    
Yamamoto[34] 2010 DCD vs 
HBD 
40 60 (DCD) 8,3 vs 18,7 
(DCD vs HBD) 
37,5 vs 
6,2  
(HAT 
33,3 vs 
0,0) 
12,5 vs 
31,2 
DCD vs 
HBD 
61,9 vs 
63,6 
 42,9 vs 
54,5 
42,9 vs 54,5  
(20yr 38,1 vs 
36,4) 
DCD vs 
HBD 
 
54,2 vs 
43,8 
 37,5 vs 
37,5 
37,5 
vs 
37,5 
(20 
yr 
29,2 
vs 
25,0) 
Nemes[18] 2010 4 Groups: 
G/G = 
good-to-
good 
B/G bad-
to-good 
G/B = 
good-to-
bad 
B/B  = 
bad-to-bad 
260 43 (112) 
B/G 28,8 
(75) 
B/B 14,2 
(37) 
G/G 10 
B/G 17 
G/B 30,5 
B/B  35 
  G/G 
B/G 
G/B 
B/B 
93  
84 
82 
83 
86 
79 
79 
83 
83 
75,5 
72 
83 
 G/G 
B/G 
G/B 
B/B 
88  
83 
81 
83 
82 
76 
78 
83 
79 
73 
72 
83 
 
Nguyen[68] 2010 SCD vs 
ECD vs 
DCD 
467 49 (DCD:4 
DBD+ECD
: 45) 
4,7 
1,7 
5,3 
15,9 
22,6 
26,3 
19,6 
8,5 
15,8 
 84,3 
85 
89,5 
80,7 
78,6 
89,5 
76,5 
72,3 
89 
      
Marthur[129] 2010 SRTR data 
(DCD) 
22 656 7   13,6 
(DCD) 
  78,4 64.9       
Briceno[1] 2010 ECD 
scores: 
0,1,2,3 
675 47 0=14,8; 1=19,2 
2= 27,5; 3=37,4 
            
Nafidi[130] 2010 new 
factors* 
634 <2000:46 
≥2000:56,9 
           71,6 vs 
70,6 
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Continued Table 2. 
Palmiero[2] 2010 new 
factors** 
ECD 
<1,7 vs 
≥1,7 
1 786 preMELD 
era: 37,5 
postMELD 
era: 43,7 
    70 vs 
64 
65 vs 
60 
61 vs 
56 
      
Serrano[131] 2010 by 
donor 
age only 
149 31  4,9  
17 
 no difference   86,7  
71,4 
   
Briceno[69] 2010 1) all 
HRS 
patients 
2) by 
graft 
steatosis 
% 
550 (all) 59 
ECD-0: 
40,9 
ECD-1: 
27,9 
ECD-2: 
16,5 
ECD-3: 
14,6 
       steatosis 
0%: 85 
10-30%: 
78 
30-60%: 
76 
> 60%: 
49 
     
Kim[132] 2011 ECD 
factors 
0-4 
100 100% elder 
than 65 
years 
           0=100%,1=82% 
2=81,7% 
3=39,3% 
4=25% 
 
Hong[107] 2011 ECD 
score 
0-1; 2-4; 
and >4 
81   BC: 
29 
IC: 
9,9 
         0-1:83 2-4:62 
>4: 0 
 
Jay[31] 2011 SRTR 
data 
43 
367 
2,6 (DCD 
only) 
  6,8 vs 
14,7 
 86 vs 
82 
86 vs 
77 
       
Jay[32] 2011 Meta-
analysis 
(1950-
2009) 
4944 9,8  
(DCD 
only) 
1 yr 
mortality 
 IC: 
3 vs 
16 
  OR: 
1,6 vs 
2,1 
        
DeOliveira[37] 2011 DCD vs 
DBD 
adult + 
pediatric 
500 33,4 
(DCD) 
DCD vs DBD: 19,7 
vs 
12,5 
(IC: 
2,4 vs 
0,0) 
1,19 vs 
1,2 
DCD 
vs 
DBD 
P = 
0.193 
P = 
0.144 
P = 
0.113 
 DCD 
vs 
DBD 
P = 
0.108 
P = 
0.173 
P = 0.236  
Foley[36] 2011 DCD vs 
DBD 
1244 6,99 DCD vs DBD: 47 vs 
26 
(IC: 
19,0 vs 
4,8 
DCD 
vs 
DBD 
84 vs 
91 
72 vs 
85 
68 vs 
81 
54 vs 67 
(15yr 54 
vs 58) 
DCD 
vs 
DBD 
69 vs 
86 
60 vs 
80 
56 vs 76 43 
vs 
60 
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34 vs 
1) 
(15yr 
43 
vs 
51) 
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Continued Table 2. 
Vagefi[29] 2011 only split 
livers, adult & 
pediatric, 
ex vivo & in 
vivo 
106 
adult 63 
children 
43 
 PNF: 
adult 1,6 
children 2,3 
adult 
28,6 
children 
39,5 
adult 
3,2 
children 
16,3 
adults 
overall 
adults 
ex vivo 
adults in 
situ 
children 
overall 
children 
ex vivo 
children 
in situ 
93 
 
93 
 
94 
 
84 
 
83 
 
86 
 
 77 
 
85 
 
75 
 
75 
 
73 
 
86 
73 
 
74 
 
NA 
 
69 
 
73 
 
NA 
adults 
overall 
adults 
ex vivo 
adults in 
situ 
children 
overall 
children 
ex vivo 
children 
in situ 
89 
 
86 
 
94 
 
77 
 
75 
 
86 
 76 
 
77 
 
75 
 
63 
 
59 
 
86 
65 
 
63 
 
NA 
 
57 
 
59 
 
NA 
Mallik[30] 2012 eRLG 
vs DCD 
49 eRLG 
34,7 
DCD 
65,3 
           71 
93 
 
Fondevila[44] 2012 only 
Maastricht type 
2  DCD 
34  NA 12 (IC 
8) 
8  82     70    
Harring[70] 2012 DCD, 
UNOS/OPTN 
database 
87499 
(DBD: 
85148, 
DCD: 
2351) 
DCD  
2,68 
PNF: 12 60  DCD vs 
DBD 
adult  
 
pediatric 
84,4 
vs 
86,1 
84,3 
vs 
86,1 
90,2 
vs 
86,6 
74,8 
vs 
78,3 
74,5 
vs 
77,8 
90,2 
vs 
82,8 
68,9 
vs 
72,5 
68,4 
vs 
71,6 
90,2 
vs 
80,8 
48,8 vs 
59,0 
47,8 vs 
57,0 
90,2 vs 
76,6 
DCD vs 
DBD 
adult  
 
pediatric 
75,3 
vs 
81,5 
75,1 
vs 
81,7 
85,6 
vs 
79,5 
63,9 
vs 
72,8 
63,7 
vs 
72,7 
76,7 
vs 
73,7 
56,2 
vs 
66,5 
55,9 
vs 
66,1 
72,4 
vs 
70,5 
38,7 
vs  
52,8 
38,1 
vs  
51,4 
64,4 
vs 
64,4 
Ghinolfi[133] 2014 Age<60 
61-69 
70-79 
>80 
842 n.a.     90,5 
88,6 
87,6 
84,7 
 78,6 
81,3 
75,1 
77,1 
      
Hoyer[134] 2014 Donor CA 
yes vs no 
884      76 
75 
 57 
53 
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Continued Table 2. 
Aseni[83] 2014 WG vs 
FRFLSLT 
1263 5,1       83,1 
63,4 
(FL 67,2 
FR 59,3) 
    80,4 
58,8 
(FL 60,7 
FR 56,6) 
 
Maggi[78] 2015 WG vs 
eRLG 
2473 7,4       76,5 
81,8 
    75,3 
79,6 
 
*Nafidi et al (2010).: Significant risk factors for graft loss: CIT>12 hours; graft gross appearance; donor partial O2 ratio<300 mm Hg; donor Hbg >100 g/L 
** Palmiero et al (2010): Significant risk factors for graft loss: CIT >9 hours ECD score >1.5; MELD ≥25; WL time >12 months 
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Table3: Different types of preservation methods of the donor graft after ECD liver 
transplantation.  
Reference Method Population Groups advantages of the method 
Rougemont 
(2009)[87] 
HOPE (one hour 
hypothermic oxygenated 
perfusion) 
Swiss landrace 
pigs 
HOPE (n=6)vs 
CS (n=6) 
survival, ATP recovery during 
reperfusion, glutathione, histology 
Bessems 
(2007)[90] 
24-hour liver 
preservation 
Wistar rat MP (n=7) vs CS 
(n=7) 
bile production, ATP levels, tissue 
oedema after reperfusion, histology 
score, oxygen consumption 
Franchello 
(2009)[91] 
10min ischeamic 
preconditioning 
deceased liver 
donors 
IP+(n=30) vs IP-
(n=45) (subgroups 
margial vs non-
marginal) 
bile production, hepatoprotective effect, 
AST and ALT level reduction 1.,3. 
postop day 
Olschewski 
(2010)[92] 
MP on different 
temperature (4,12,21C) 
Wistar rat  portal venous resistance, bile flow 
(MPat21C),ALT after reperfusion,  
Schmeding 
(2010)[93] 
rHuEpo 4 hours after 
liver transplantation 
Lewis rat rHuEpo (+) n=35 
vs rHUEpo(-) 
n=35 and n=70 
recipients 
ALT,AST (48h postolt), overall survival, 
cell apoptosis/necrosis 
Mangus (2008)[94] HTK vs UW human DCD n=698 HTK may be protective against biliary 
complications when compared to UW. 
Stegemann 
(2010)[95] 
modified HTK 
(Custadiol-N) 
Wistar rat (non-
heart beating) 
 significant enhancement of CO2 
production and thus effective 
aerobic metabolism 
Guarrera 
(2010)[98] 
HMP (3-7 hours) human HMP (n=20) vs 
CS (n=20) 
early allograft dysfunction, hospital 
length of stay, serum levels of markers 
of liver injury and renal function 
Obara (2013)[86] new machine perfusion 
preservation system 
(NES-01) with 
tempreture controll 
porcine n=3 pressure transition, LDH levels 
Dutkowski 
(2013)[89] 
HOPE human DCD DCD 
donor+HOPE(n=
8) vs DBD (n=8) 
reperfusion injury was low in machine 
perfused DCD livers 
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